SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease
NCT02605603 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2019-08-13
Summary
This project is expected to elucidate role of different therapeutic interventions: SRT in comparison to ERT in influencing immune aspects of GD pathology, as well as bone involvement.
Conditions
- Gaucher Disease
Sponsors & Collaborators
-
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
lead OTHER
Principal Investigators
-
Ozlem Goker-Alpan, MD · Study Principle Investigator
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-05-31
- Primary Completion
- 2020-02-29
- Completion
- 2020-05-31
Countries
- United States
Study Locations
More Related Trials
-
A Screening Study Evaluating Disease Status of Gaucher Type I Patients
NCT00795197 ·Status: WITHDRAWN
-
Gaucherite - A Study to Stratify Gaucher Disease
NCT03240653 ·Status: RECRUITING
-
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
NCT00635427 ·Status: COMPLETED ·Phase: PHASE3
-
Natural History of Rett Syndrome & Related Disorders
NCT02738281 ·Status: COMPLETED
-
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
NCT05815004 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Assessment Of Liver and Spleen Fibrosis in Patients With Gaucher Disease Using Fibroscan
NCT01898325 ·Status: UNKNOWN ·Phase: NA
-
Pharmacological Treatment of Rett Syndrome With Statins
NCT02563860 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02
NCT04836377 ·Status: TERMINATED
-
Gene Editing as a Therapeutic Approach for Rett Syndrome
NCT05740761 ·Status: RECRUITING
-
Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease
NCT04145037 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Macrophagic Activation and Immunophenotypic Profile of Patients With Gaucher's Disease
NCT01206673 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
NCT02790034 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
NCT02228460 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease
NCT00319046 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Follow-Up for Safety of AVR-RD-02
NCT06488261 ·Status: ACTIVE_NOT_RECRUITING
-
Gaucher Disease Outcome Survey (GOS)
NCT03291223 ·Status: RECRUITING
-
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease
NCT02416661 ·Status: COMPLETED
-
Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease
NCT02437396 ·Status: RECRUITING
-
Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)
NCT05908656 ·Status: COMPLETED ·Phase: NA
-
GCB-002 in Treatment of Patients With Rett Syndrome
NCT06739434 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
NCT02843035 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Identification of Undiagnosed Gaucher Disease
NCT01716741 ·Status: UNKNOWN ·Phase: NA
-
A Natural History of Late Onset Tay-Sachs Disease
NCT02851862 ·Status: COMPLETED
-
A Gene Therapy Study in Patients With Gaucher Disease Type 1
NCT05324943 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease
NCT00004293 ·Status: UNKNOWN ·Phase: PHASE2